NCT06208332 The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
| NCT ID | NCT06208332 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Seattle Children's Hospital |
| Condition | Critical Illness |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-02-10 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 160 participants in total. It began in 2025-02-10 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to conduct a pilot randomized controlled trial (RCT) of a photo-narrative communication intervention developed by our study team with patients/parents of children with severe neurological impairment (SNI) and their pediatric intensive care unit (PICU) clinicians to assess feasibility, acceptability, and early efficacy.
Eligibility Criteria
Children with SNI Inclusion * Hospitalized at study sites * Ages 6 months through 25 years old * Has had SNI for \>6 months, defined as permanent static or progressive central nervous system injury resulting in motor/cognitive impairment and medical complexity Exclusion * Has never previously been home/discharged * Has an expected hospital length of stay \<2 days * Has a life expectancy of \<4 weeks * Previous study participation Parents Inclusion * Parent/legally authorized representative of an eligible child with SNI * Preferred language of care English and/or Spanish Clinicians Inclusion -Licensed physicians, nurses, advanced practice providers, respiratory therapists at study site Exclusion -Previous study participation
Contact & Investigator
Jori Bogetz, MD
PRINCIPAL INVESTIGATOR
Seattle Children's Hospital
Frequently Asked Questions
Who can join the NCT06208332 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06208332 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06208332 currently recruiting?
Yes, NCT06208332 is actively recruiting participants. Contact the research team at jori.bogetz@seattlechildrens.org for enrollment information.
Where is the NCT06208332 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06208332 clinical trial?
NCT06208332 is sponsored by Seattle Children's Hospital. The principal investigator is Jori Bogetz, MD at Seattle Children's Hospital. The trial plans to enroll 160 participants.